

Food and Drug Administration Rockville MD 20857

01 NOV 20 AP 24

Mr. Patrick Mcgrath, Jr. 2931 Edgewood Avenue Parkville, Maryland 21234

Dear Mr. Mcgrath:

Thank you for your electronic message of August 22, 2001, addressed to Senator Barbara A. Mikulski, regarding Food and Drug Administration (FDA) docket 01N-0256: "Use of Opiate Analgesics in Various Patient Population, including Pediatric Patients." Senator Mikulski has asked us to respond directly to you.

We appreciate knowing your concerns regarding opoid and opoidrelated drugs. We are forwarding your correspondence to the Dockets Management Branch. If you would like to contact them directly, the address is provided below:

> Dockets Management Branch 5630 Fishers Lane, Room 1061, HFA-305 Rockville, Maryland 20852 Telephone number: 301-827-6860

Controlled substances and production quotas are the jurisdiction of the Drug Enforcement Administration. You may contact them directly:

> Drug Enforcement Administration Office of Diversion Control 2401 Jefferson Davis Highway Alexandria, Virginia 22301

Thanks for contacting Senator Mikulski concerning this matter.

Sincerely,

Associate Commissioner

for Legislation

011-0236

C 322/ANS

Page 2 - Mr. Patrick Mcgrath, Jr.

The Honorable Barbara A. Mikulski United States Senate Washington, D.C. 20510-2003

SUITE 709 HART SENATE OFFICE BUILDING WASHINGTON, DC 20510-2003

(202) 224–4654 TDD: (202) 224–5223 http://mikulski.sanate.gov/

United States Senate

WASHINGTON, DC 20510-2003

September 28, 2001

Ms. Melinda Palisier
Associate Commissioners for Legislation
Food and Drug Administration
U. S. Department of Health & Human Svcs.
5600 Fishers Lane, Room 15-55
Parklawn Building
Rockville, Maryland 20857-0002

Dear Ms. Palisier:

I am writing to request your consideration of the attached correspondence from Mr. Patrick McGrath, Jr.. Please respond directly to Mr. McGrath and send a copy to Amy Short of my staff. If you have any questions, please call Amy Short at (202) 224-4654.

Thank you for your assistance.

Sincerely,

Barbara A. Mikulski United States Senator

BAM:mh Enclosure

-5010

a mouth

nobody@w1.senate.gov at Internet 08/22/2001 12:41 AM

rmal

TO: mailroom at Mikulski-DC Subject: email Senator Mikulski

----- Message Contents

01Prefix= Mr.
02first= Patrick
03last= Mcgrath Jr.
04adl= 2931 Edgewood Ave.
05city= Parkville
06state= Md
07zip= 21234

08from= jp.mcgrath1@home.com

comment= Hon.Senator Mikulski; FDA-docket 01N-0256 is proposing a reduction in opoid and opoid related drugs. These proposed actions include limiting the drug companies production quotes; removing certain very strong narcotics and alternate analgesic drugs. They are also pressuring doctors about the number and type of prescriptions, in particular, chronic and acute pain patients. I'm a chronic pain patient. I'm totally disabled from a condition known as arachnoiditis which is degenerative and progressive. It has no cure and the current treatments are only pain management treatments. These treatments use several methods but all involve pain killer type drugs. Recently, I have developed an allergic codeine and almost all opoid-base medications. This has created a very difficult problems for my doctor's and myself. If FDA and DEA reduce our doctors ablitity to use any of these pain relievers or future drugs thousands of pain sufferer's will be condemmed to suffer without hope. Please do

anything You can to he